Last reviewed · How we verify
NCT05166057
Telerehabilitation in Patients With Fibrosing Interstitial Lung Diseases
NA trial testing Synchronized online telerehabilitation exercise program in Fibrosing Interstitial Lung Disease in 63 participants. Completed in 30 May 2025.
30 May 2025
Quick facts
| Lead sponsor | Saglik Bilimleri Universitesi |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 63 |
| Start date | 22 January 2022 |
| Primary completion | 30 May 2025 |
| Estimated completion | 30 May 2025 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Synchronized online telerehabilitation exercise program
- Videobased telerehabilitation exercise program
- Hospital based outpatient exercise program
Conditions studied
- Fibrosing Interstitial Lung Disease — all drugs for Fibrosing Interstitial Lung Disease →
- Telerehabilitation — all drugs for Telerehabilitation →
Sponsor
Saglik Bilimleri Universitesi — full company profile →
Who can join
Adults 18 to 75, any sex, with Fibrosing Interstitial Lung Disease or Telerehabilitation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study is to determine the effectiveness of different exercise programs applied to 3 groups randomly formed in patients with fibrosing interstitial lung disease (FILD). Secondary purpose: To determine the feasibility and effectiveness of telerehabilitation in FILD cases.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Home-based rehabilitation in interstitial lung disease: picturing the present and drawing the future through a systematic review of the literature.
Bongiovanni G, Polelli V, Stainer A, Russo M, et al · · 2026 · PMID 42111388 · DOI 10.1183/23120541.00879-2025 -
The impact of different pulmonary rehabilitation approaches on fibrotic interstitial lung disease: a comparative randomized trial.
Pehlivan E, Çetinkaya E, Karaahmetoğlu FS, Özcan ZB, et al · · 2025 · PMID 40440705 · DOI 10.1080/17476348.2025.2513512
Verify or expand the search:
- PubMed search for NCT05166057
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Fibrosing Interstitial Lung Disease
Currently open trials in the same condition.
- NCT06855004 — Prospective Cohort of Patients With Fibrosing Interstitial Lung Disease Admitted for Acute Respiratory Failure · recruiting
Other Saglik Bilimleri Universitesi trials
Trials by the same sponsor.
- NCT07499986 — Respiratory Muscle Training in Patients Undergoing Lung Cancer Surgery · NA · not yet recruiting
- NCT07516340 — Gamification-Based Peer Education in Nursing Students: Effects on Sexual Health Literacy and Attitudes · NA · not yet recruiting
- NCT07520435 — Short-Term Mindfulness Intervention for Anxiety and Maternal Attachment in NICU Mothers · NA · not yet recruiting
- NCT07528001 — Hypno-Breastfeeding Education and Postpartum Outcomes · NA · not yet recruiting
- NCT07344649 — Turkish Validation of the Nijmegen Questionnaire in COPD · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05166057 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Saglik Bilimleri Universitesi
- Last refreshed: 22 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05166057.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing